|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Dillman RO, Herndon J, Seagren SL, Eaton
WL Jr and Green MR: Improved survival in stage III non-small-cell
lung cancer: seven year follow-up of cancer and leukemia group B
(CALGB) 8433 trial. J Natl Cancer Inst. 88:1210–1215.
1996.PubMed/NCBI
|
|
3
|
Furuse K, Fukuoka M, Kawahara M, Nishikawa
H, Takada Y, Kudoh S, Katagami N and Ariyoshi Y: Phase III study of
concomitant versus sequential thoracic radiotherapy in combination
with mitomycin, vindesine, and cisplatin in unresectable stage III
non-small cell lung cancer. J Clin Oncol. 17:2692–2699.
1999.PubMed/NCBI
|
|
4
|
Liang HY, Zhou H, Li XL, Yin ZH, Guan P
and Zhou BS: Chemo-radiotherapy for advanced non-small cell lung
cancer: concomitant or sequential? It's no longer the question: a
systematic review. Int J Cancer. 127:718–728. 2010. View Article : Google Scholar
|
|
5
|
Perez CA, Pajak TF, Rubin P, Simpson JR,
Mohiuddin M, Brady LW, Perez-Tamayo R and Rotman M: Long-term
observations of the patterns of failure in patients with
unresectable non-oat cell carcinoma of the lung treated with
definitive radiotherapy. Report by the Radiation Therapy Oncology
Group. Cancer. 59:1874–1881. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bradley J: A review of radiation dose
escalation trials for non-small cell lung cancer within the
Radiation Therapy Oncology Group. Semin Oncol. 32:S111–S113. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bradley JD, Moughan J, Graham MV, Byhardt
R, Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E and Choy H:
A phase I/II radiation dose escalation study with concomitant
chemotherapy for patients with inoperable stages I to III
non-small-cell lung cancer: phase I results of RTOG 0117. Int J
Radiat Oncol Biol Phys. 77:367–372. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Graham MV, Purdy JA, Emami B, Harms W,
Bosch W, Lockett MA and Perez CA: Clinical dose-volume histogram
analysis for pneumonitis after 3D treatment for non-small cell lung
cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45:323–329.
1999.PubMed/NCBI
|
|
9
|
Wang S, Liao Z, Wei X, Liu HH, Tucker SL,
Hu CS, Mohan R, Cox JD and Komaki R: Analysis of clinical and
dosimetric factors associated with treatment-related pneumonitis
(TRP) in patients with non-small-cell lung cancer (NSCLC) treated
with concomitant chemotherapy and three-dimensional conformal
radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 66:1399–1407.
2006. View Article : Google Scholar
|
|
10
|
Yang LQ, Wu LP, Chen LJ, Zhang RN, Gao YQ,
Chen GY and Liang NQ: Value of V20 and V30 parametres for
predicting acute radiation lung toxicity after 3D radiotherapy for
lung cancer. Chin J Cancer Prev Treat (In Chinese). 15:280–282.
2008.
|
|
11
|
Zhu GY, Xia TY, Wang LH, Gao XS, Wang JJ,
Li AF, Zhang FQ, Ma L, Li YX and Xu B: Consensus and controversies
on delineation of radiotherapy target volume for patients with
non-small cell lung cancer. Chin J Radiat Oncol (In Chinese).
17:432–436. 2008.
|
|
12
|
Trotti A, Byhardt R, Stetz J, Gwede C,
Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T,
Shipley W and Curran W: Common toxicity criteria: version 2.0. An
improved reference for grading the acute effects of cancer
treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys.
47:13–47. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun Y and Zhou J: Medical Oncology [M]
(4th edition). People's Medical Publishing House (In Chinese).
Beijing: 106–107. 2004.
|
|
14
|
El-Sharouni SY, Kal HB, Battermann JJ and
Schramel FM: Sequential versus concomitant chemo-radiotherapy in
inoperable stage III non-small cell lung cancer. Anticancer Res.
26:495–505. 2006.PubMed/NCBI
|
|
15
|
Sause W, Kolesar P, Taylor S IV, Johnson
D, Livingston R, Komaki R, Emami B, Curran W Jr, Byhardt R, Dar AR
and Turrisi A III: Final results of phase III trial in regionally
advanced unresectable non-small cell lung cancer: Radiation Therapy
Oncology Group, Eastern Cooperative Oncology Group, and Southwest
Oncology Group. Chest. 117:358–364. 2000. View Article : Google Scholar
|
|
16
|
Schaake-Koning C, van den Bogaert W,
Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A,
Koolen M, Maat B and Nijs A: Effects of concomitant cisplatin and
radiotherapy on inoperable non-small-cell lung cancer. N Engl J
Med. 326:524–530. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fletcher GH: Clinical dose response curves
of human malignant epithelial tumors. Br J Radiol. 46:1511973.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Onishi H, Shirato H, Nagata Y, Hiraoka M,
Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura
T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada
K and Araki T: Hypofractionated stereotactic radiotherapy
(HypoFXSRT) for stage I non-small cell lung cancer: updated results
of 257 patients in a Japanese multi-institutional study. J Thorac
Oncol. 2:S94–S100. 2007. View Article : Google Scholar
|
|
19
|
Lichter AS and Lawrence TS: Recent
advances in radiation oncology. N Engl J Med. 332:371–379. 1995.
View Article : Google Scholar
|
|
20
|
Lin Q, Gao XS, Qiao XY, Zhou ZG, Zhang P
and Yang XR: Dose escalation of cisplatin with 5-fluororacil in
concomitant chemoradiotherapy for esophageal carcinoma. Chin J
Radiat Oncol (In Chinese). 15:301–304. 2006.
|
|
21
|
Lin Q, Gao XS, Qiao XY, Zhou ZG, Zhang P,
Chen K, Zhao YN and Asaumi J: Phase I trial of escalating-dose
cisplatin with 5-fluorouracil and concomitant radiotherapy in
Chinese patients with esophageal cancer. Acta Med Okayama.
62:37–44. 2008.PubMed/NCBI
|
|
22
|
Vokes EE, Herndon JE II, Crawford J,
Leopold KA, Perry MC, Miller AA and Green MR: Randomized phase II
study of cisplatin with gemcitabine or paclitaxel or vinorelbine as
induction chemotherapy followed by concomitant radiochemotherapy
for stage IIIB non-small-cell lung cancer: cancer and leukemia
group B study 9431. J Clin Oncol. 20:4191–4198. 2002. View Article : Google Scholar
|
|
23
|
Zhang ZM, Zhao HY, Zhang CJ and Mu JG:
Vinorelbine and carboplatin with concomitant radiotherapy in
locally advanced non-small cell lung cancer. Chin J Clin Oncol (In
Chinese). 9:625–627. 2004.
|
|
24
|
Rao CY: Study of concomitant versus
sequential radiochemotherapy with vinorelbine and cisplatin in
stage III non-small cell lung cancer. Chin J Cancer Prev Treat (In
Chinese). 14:942–943. 2007.
|
|
25
|
Liu J, Lv CX, Wang JM, Li HX, Guo JD, Wang
CL, Gao LT and Zhao L: Analysis of two different concomitant
radiochemotherapy regimens in the treatment of locally advanced
stage III non-small cell lung cancer. Chin J Clin Oncol (In
Chinese). 15:226–229. 2010.
|
|
26
|
Wang JP, Zhai XM, Zhang JN and Xu CS:
Clinical study on concomitant radiotherapy in combination with
vinorelbine and cisplatin for advance non-small cell lung cancer.
Acta Med Jiangsu Univ (In Chinese). 16:483–485. 2005.
|
|
27
|
Lu DJ, Wang L, Han C, Gao C and Li XN:
Toxicity analysis for esophagus in locally advanced non-small cell
lung cancer treatment using three dimensional conformal
radiotherapy combined with concomitant chemotherapy. Chin J Radiol
Med Prot (In Chinese). 30:185–188. 2010.
|
|
28
|
Zheng JX, Niu DL and Xu K: Radiotherapy
combined with concomitant chemotherapy for stage III non-small cell
lung cancer. Chin J Cancer Prev Treat (In Chinese). 13:1822–1823.
2006.
|
